Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) / Gargiulo, Luigi; Ibba, Luciano; Cascio Ingurgio, Ruggero; Malagoli, Piergiorgio; Amoruso, Fabrizio; Balato, Anna; Bardazzi, Federico; Brianti, Pina; Brunasso, Giovanna; Burlando, Martina; Cagni, Anna E.; Caproni, Marzia; Carrera, Carlo G.; Carugno, Andrea; Caudullo, Francesco; Cuccia, Aldo; Dapavo, Paolo; Di Brizzi, Eugenia V.; Dini, Valentina; Gaiani, Francesca M.; Gisondi, Paolo; Guarneri, Claudio; Lasagni, Claudia; Licata, Gaetano; Loconsole, Francesco; Marzano, Angelo V.; Megna, Matteo; Mercuri, Santo R.; Musumeci, Maria L.; Orsini, Diego; Ribero, Simone; Ruffo Di Calabria, Valentina; Satolli, Francesca; Strippoli, Davide; Travaglini, Massimo; Trovato, Emanuele; Venturini, Marina; Zichichi, Leonardo; Valenti, Mario; Costanzo, Antonio; Narcisi, Alessandra. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - 35:1(2024). [10.1080/09546634.2024.2350760]

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

Megna, Matteo;
2024

Abstract

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.
2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) / Gargiulo, Luigi; Ibba, Luciano; Cascio Ingurgio, Ruggero; Malagoli, Piergiorgio; Amoruso, Fabrizio; Balato, Anna; Bardazzi, Federico; Brianti, Pina; Brunasso, Giovanna; Burlando, Martina; Cagni, Anna E.; Caproni, Marzia; Carrera, Carlo G.; Carugno, Andrea; Caudullo, Francesco; Cuccia, Aldo; Dapavo, Paolo; Di Brizzi, Eugenia V.; Dini, Valentina; Gaiani, Francesca M.; Gisondi, Paolo; Guarneri, Claudio; Lasagni, Claudia; Licata, Gaetano; Loconsole, Francesco; Marzano, Angelo V.; Megna, Matteo; Mercuri, Santo R.; Musumeci, Maria L.; Orsini, Diego; Ribero, Simone; Ruffo Di Calabria, Valentina; Satolli, Francesca; Strippoli, Davide; Travaglini, Massimo; Trovato, Emanuele; Venturini, Marina; Zichichi, Leonardo; Valenti, Mario; Costanzo, Antonio; Narcisi, Alessandra. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - 35:1(2024). [10.1080/09546634.2024.2350760]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/959547
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact